1
|
Martins NDS, Rodrigues APS, Bicalho JM, Albuquerque JJ, Reis LL, Alves LL, de Oliveira RM, Santos LSD, de Carvalho Neta AV, de Oliveira RA, Carvalho RC, Melo FA, Dos Reis JKP, Abreu-Silva AL. Molecular characterization of Brazilian FeLV strains in São Luis, Maranhão Brazil. Virus Genes 2023:10.1007/s11262-023-01997-x. [PMID: 37195404 DOI: 10.1007/s11262-023-01997-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 04/11/2023] [Indexed: 05/18/2023]
Abstract
The feline leukemia virus (FeLV) belongs to the Retroviridae family and Gammaretrovirus genus, and causes a variety of neoplastic and non-neoplastic diseases in domestic cats (Felis catus), such as thymic and multicentric lymphomas, myelodysplastic syndromes, acute myeloid leukemia, aplastic anemia, and immunodeficiency. The aim of the present study was to carry out the molecular characterization of FeLV-positive samples and determine the circulating viral subtype in the city of São Luís, Maranhão, Brazil, as well as identify its phylogenetic relationship and genetic diversity. The FIV Ac/FeLV Ag Test Kit (Alere™) and the commercial immunoenzymatic assay kit (Alere™) were used to detect the positive samples, which were subsequently confirmed by ELISA (ELISA - SNAP® Combo FeLV/FIV). To confirm the presence of proviral DNA, a polymerase chain reaction (PCR) was performed to amplify the target fragments of 450, 235, and 166 bp of the FeLV gag gene. For the detection of FeLV subtypes, nested PCR was performed for FeLV-A, B, and C, with amplification of 2350-, 1072-, 866-, and 1755-bp fragments for the FeLV env gene. The results obtained by nested PCR showed that the four positive samples amplified the A and B subtypes. The C subtype was not amplified. There was an AB combination but no ABC combination. Phylogenetic analysis revealed similarities (78% bootstrap) between the subtype circulating in Brazil and FeLV-AB and with the subtypes of Eastern Asia (Japan) and Southeast Asia (Malaysia), demonstrating that this subtype possesses high genetic variability and a differentiated genotype.
Collapse
Affiliation(s)
- Nathálya Dos Santos Martins
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Ana Paula Sousa Rodrigues
- Department of Preventive Veterinary Medicine, School of Veterinary Medicine, Federal University of Minas Gerais, UFMG 30 123-970, Belo Horizonte, MG, Brazil
| | - Juliana Marques Bicalho
- Department of Preventive Veterinary Medicine, School of Veterinary Medicine, Federal University of Minas Gerais, UFMG 30 123-970, Belo Horizonte, MG, Brazil
| | - Joanna Jéssica Albuquerque
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Luana Luz Reis
- Laboratory of Genetics and Molecular Biology, Department of Chemistry and Biology, State University of Maranhão (UEMA), Praça Duque de Caxias, s/n, Morro do Alecrim, Caxias, MA, 65604-380, Brazil
| | - Luciana Luz Alves
- Laboratory of Genetics and Molecular Biology, Department of Chemistry and Biology, State University of Maranhão (UEMA), Praça Duque de Caxias, s/n, Morro do Alecrim, Caxias, MA, 65604-380, Brazil
| | - Renata Mondego de Oliveira
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Larissa Sarmento Dos Santos
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Alcina Vieira de Carvalho Neta
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Rudson Almeida de Oliveira
- Department of Veterinary Clinics, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Rafael Cardoso Carvalho
- Center for Biological and Health Sciences, Federal University of Maranhão, UFMA, Rodovia BR 222, Km 04, s/n, Boa Vista, Chapadinha, MA, 65500-000, Brazil
| | - Ferdinan Almeida Melo
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil
| | - Jenner Karlisson Pimenta Dos Reis
- Department of Preventive Veterinary Medicine, School of Veterinary Medicine, Federal University of Minas Gerais, UFMG 30 123-970, Belo Horizonte, MG, Brazil
| | - Ana Lucia Abreu-Silva
- Departament of Pathology, State University of Maranhão, University City Paulo VI, Cx. Postal 9, Tirirical, São Luís, MA, 65055-970, Brazil.
| |
Collapse
|
2
|
Westman M, Norris J, Malik R, Hofmann-Lehmann R, Parr YA, Armstrong E, McDonald M, Hall E, Sheehy P, Hosie MJ. Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax ® Lv-K and Fel-O-Vax ® 5). Viruses 2021; 13:240. [PMID: 33546485 DOI: 10.3390/v13020240] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 01/29/2021] [Accepted: 02/02/2021] [Indexed: 12/16/2022] Open
Abstract
A field study undertaken in Australia compared the antibody responses induced in client-owned cats that had been vaccinated using two inactivated whole feline leukaemia virus (FeLV) vaccines, the monovalent vaccine Fel-O-Vax® Lv-K and the polyvalent vaccine Fel-O-Vax® 5. Serum samples from 428 FeLV-uninfected cats (118 FeLV-vaccinated and 310 FeLV-unvaccinated) were tested for anti-FeLV neutralising antibodies (NAb) using a live virus neutralisation assay to identify 378 FeLV-unexposed (NAb-negative) and 50 FeLV-exposed (NAb-positive; abortive infections) cats, following by anti-surface unit (SU) FeLV-A and FeLV-B antibody ELISA testing. An additional 42 FeLV-infected cats (28 presumptively regressively infected, 14 presumptively progressively infected) were also tested for anti-SU antibodies. NAb-positive cats displayed significantly higher anti-SU antibody ELISA responses compared to NAb-negative cats (p < 0.001). FeLV-unexposed cats (NAb-negative) that had been vaccinated less than 18 months after a previous FeLV vaccination using the monovalent vaccine (Fel-O-Vax® Lv-K) displayed higher anti-SU antibody ELISA responses than a comparable group vaccinated with the polyvalent vaccine (Fel-O-Vax® 5) (p < 0.001 for both anti-FeLV-A and FeLV-B SU antibody responses). This difference in anti-SU antibody responses between cats vaccinated with the monovalent or polyvalent vaccine, however, was not observed in cats that had been naturally exposed to FeLV (NAb-positive) (p = 0.33). It was postulated that vaccination with Fel-O-Vax® 5 primed the humoral response prior to FeLV exposure, such that antibody production increased when the animal was challenged, while vaccination with Fel-O-Vax® Lv-K induced an immediate preparatory antibody response that did not quantitatively increase after FeLV exposure. These results raise questions about the comparable vaccine efficacy of the different FeLV vaccine formulations and correlates of protection.
Collapse
|
3
|
Abstract
PRACTICAL RELEVANCE Feline leukaemia virus (FeLV) is a retrovirus of domestic cats worldwide. Cats lacking strong FeLV-specific immunity and undergoing progressive infection commonly develop fatal FeLV-associated disease. Many aspects of FeLV infection pathogenesis have been elucidated, some during more recent years using molecular techniques. It is recommended that the FeLV status of every cat is known, since FeLV infection can influence the prognosis and clinical management of every sick cat. Moreover, knowledge of a cat's FeLV status is of epidemiological importance to prevent further spread of the infection. CLINICAL CHALLENGES Diagnosing FeLV infection remains challenging due to different outcomes of infection, which can vary over time depending on the balance between the virus and the host's immune system. Furthermore, testing for FeLV infection has become more refined over the years and now includes diagnostic assays for different viral and immunological parameters. Knowledge of FeLV infection pathogenesis, as well as the particulars of FeLV detection methods, is an important prerequisite for correct interpretation of any test results and accurate determination of a cat's FeLV status. AIMS The current review presents recent knowledge on FeLV pathogenesis, key features to be determined in FeLV infection, and frequently used FeLV detection methods, and their characteristics and interpretation. An algorithm for the diagnosis of FeLV infection in a single cat, developed by the European Advisory Board on Cat Diseases, is included, and FeLV testing in specific situations is addressed. As well as increasing awareness of this deadly infection in domestic cats, the aim is to contribute diagnostic expertise to allow veterinarians in practice to improve their recognition, and further reduce the prevalence, of FeLV infection.
Collapse
Affiliation(s)
- Regina Hofmann-Lehmann
- Prof, Dr med vet, FVH Professor of Laboratory Medicine, Director of Department of Clinical Diagnostics and Services, Head of Clinical Laboratory and Centre for Clinical Studies, Vetsuisse Faculty, University of Zurich, Switzerland
| | - Katrin Hartmann
- Prof, Dr med vet, Dr habil, Dip ECVIM-CA (Internal Medicine) Professor of Internal Medicine, Head of Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, Germany
| |
Collapse
|
4
|
Abstract
The guidelines are a consensus report on current recommendations for vaccination of cats of any origin, authored by a Task Force of experts. The guidelines are published simultaneously in the Journal of Feline Medicine and Surgery (volume 22, issue 9, pages 813–830, DOI: 10.1177/1098612X20941784) and the Journal of the American Animal Hospital Association (volume 56, issue 4, pages 249–265, DOI: 10.5326/JAAHA-MS-7123). The guidelines assign approved feline vaccines to core (recommended for all cats) and non-core (recommended based on an individualized risk–benefit assessment) categories. Practitioners can develop individualized vaccination protocols consisting of core vaccines and non-core vaccines based on exposure and susceptibility risk as defined by the patient’s life stage, lifestyle, and place of origin and by environmental and epidemiologic factors. An update on feline injection-site sarcomas indicates that occurrence of this sequela remains infrequent and idiosyncratic. Staff education initiatives should enable the veterinary practice team to be proficient in advising clients on proper vaccination practices and compliance. Vaccination is a component of a preventive healthcare plan. The vaccination visit should always include a thorough physical exam and client education dialog that gives the pet owner an understanding of how clinical staff assess disease risk and propose recommendations that help ensure an enduring owner–pet relationship.
Collapse
Affiliation(s)
- Amy ES Stone
- Chair of 2020 AAHA/AAFP Feline Vaccination Guidelines Task Force
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA
| | - Gary O Brummet
- DVM Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | | | - Philip H Kass
- DVM, MPVM, MS, PhD, DACVPM (Specialty in Epidemiology) Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| | - Ernest P Petersen
- DVM, PhD, DABVP (Feline) Animal Hospital of Parkland, Tacoma, Washington, USA
| | - Jane Sykes
- BVSc (Hons), PhD, DACVIM, MBA University of California, Davis, Davis, California, USA
| | - Mark E Westman
- BVSc (Hons), PhD, MANZCVS (Animal Welfare), GradCert Ed Stud (Higher Ed)) Sydney School of Veterinary Science, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
5
|
Abstract
ABSTRACT
The guidelines are a consensus report on current recommendations for vaccination of cats of any origin, authored by a Task Force of experts. The guidelines are published simultaneously in the Journal of Feline Medicine and Surgery (volume 22, issue 9, pages 813–830, DOI: 10.1177/1098612X20941784) and the Journal of the American Animal Hospital Association (volume 56, issue 4, pages 249–265, DOI: 10.5326/JAAHA-MS-7123). The guidelines assign approved feline vaccines to core (recommended for all cats) and non-core (recommended based on an individualized risk-benefit assessment) categories. Practitioners can develop individualized vaccination protocols consisting of core vaccines and non-core vaccines based on exposure and susceptibility risk as defined by the patient’s life stage, lifestyle, and place of origin and by environmental and epidemiologic factors. An update on feline injection-site sarcomas indicates that occurrence of this sequela remains infrequent and idiosyncratic. Staff education initiatives should enable the veterinary practice team to be proficient in advising clients on proper vaccination practices and compliance. Vaccination is a component of a preventive healthcare plan. The vaccination visit should always include a thorough physical exam and client education dialog that gives the pet owner an understanding of how clinical staff assess disease risk and propose recommendations that help ensure an enduring owner-pet relationship.
Collapse
Affiliation(s)
- Amy E. S. Stone
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Gary O. Brummet
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Ellen M. Carozza
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Philip H. Kass
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Ernest P. Petersen
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Jane Sykes
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| | - Mark E. Westman
- From the Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA (A.E.S.S.); Veterinary Teaching Hospital, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (G.O.B.); Nova Cat Clinic, Arlington, Virginia, USA (E.M.C.); Department of Population Health and Reproduction, School of Veterinary Medicine, University o
| |
Collapse
|
6
|
Little S, Levy J, Hartmann K, Hofmann-Lehmann R, Hosie M, Olah G, Denis KS. 2020 AAFP Feline Retrovirus Testing and Management Guidelines. J Feline Med Surg 2020; 22:5-30. [DOI: 10.1177/1098612x19895940] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Clinical importance: Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections are found in cats worldwide. Both infections are associated with a variety of clinical signs and can impact quality of life and longevity. Scope: This document is an update of the 2008 American Association of Feline Practitioners’ feline retrovirus management guidelines and represents current knowledge on pathogenesis, diagnosis, prevention and treatment of retrovirus infections in cats. Testing and interpretation: Although vaccines are available for FeLV in many countries and for FIV in some countries, identification of infected cats remains an important factor for preventing new infections. The retrovirus status of every cat at risk of infection should be known. Cats should be tested as soon as possible after they are acquired, following exposure to an infected cat or a cat of unknown infection status, prior to vaccination against FeLV or FIV, and whenever clinical illness occurs. It might not be possible to determine a cat’s infection status based on testing at a single point in time; repeat testing using different methods could be required. Although FeLV and FIV infections can be associated with clinical disease, some infected cats, especially those infected with FIV, can live for many years with good quality of life. Management of infected cats: There is a paucity of data evaluating treatments for infected cats, especially antiretroviral and immunomodulatory drugs. Management of infected cats is focused on effective preventive healthcare strategies, and prompt identification and treatment of illness, as well as limiting the spread of infection.
Collapse
Affiliation(s)
- Susan Little
- Bytown Cat Hospital, Ottawa, ON, Canada
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | - Julie Levy
- Maddie’s Shelter Medicine Program, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | - Katrin Hartmann
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, Munich, Germany
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | - Regina Hofmann-Lehmann
- Clinical Laboratory, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | - Margaret Hosie
- MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | - Glenn Olah
- Albuquerque Cat Clinic, Albuquerque, NM, USA
- Charing Cross Cat Clinic, Brantford, ON, Canada
| | | |
Collapse
|
7
|
Westman M, Norris J, Malik R, Hofmann-Lehmann R, Harvey A, McLuckie A, Perkins M, Schofield D, Marcus A, McDonald M, Ward M, Hall E, Sheehy P, Hosie M. The Diagnosis of Feline Leukaemia Virus (FeLV) Infection in Owned and Group-Housed Rescue Cats in Australia. Viruses 2019; 11:v11060503. [PMID: 31159230 PMCID: PMC6630418 DOI: 10.3390/v11060503] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 05/21/2019] [Accepted: 05/29/2019] [Indexed: 12/11/2022] Open
Abstract
A field study was undertaken to (i) measure the prevalence of feline leukaemia virus (FeLV) exposure and FeLV infection in a cross-section of healthy Australian pet cats; and (ii) investigate the outcomes following natural FeLV exposure in two Australian rescue facilities. Group 1 (n = 440) consisted of healthy client-owned cats with outdoor access, predominantly from eastern Australia. Groups 2 (n = 38) and 3 (n = 51) consisted of a mixture of healthy and sick cats, group-housed in two separate rescue facilities in Sydney, Australia, tested following identification of index cases of FeLV infection in cats sourced from these facilities. Diagnostic testing for FeLV exposure/infection included p27 antigen testing using three different point-of-care FeLV kits and a laboratory-based ELISA, real-time polymerase chain reaction (qPCR) testing to detect FeLV proviral DNA in leukocytes, real-time reverse-transcription PCR (qRT-PCR) testing to detect FeLV RNA in plasma, and neutralising antibody (NAb) testing. Cats were classified as FeLV-uninfected (FeLV-unexposed and presumptively FeLV-abortive infections) or FeLV-infected (presumptively regressive and presumptively progressive infections). In Group 1, 370 FeLV-unexposed cats (370/440, 84%), 47 abortive infections (47/440, 11%), nine regressive infections (9/440, 2%), and two progressive infections (2/440, 0.5%) were identified, and 12 FeLV-uninfected cats (12/440, 3%) were unclassifiable as FeLV-unexposed or abortive infections due to insufficient samples available for NAb testing. In Groups 2 and 3, 31 FeLV-unexposed cats (31/89, 35%), eight abortive infections (8/89, 9%), 22 regressive infections (22/89; 25%), and 19 progressive infections (19/89; 21%) were discovered, and nine FeLV-uninfected cats (9/89; 10%) were unclassifiable due to insufficient samples available for NAb testing. One of the presumptively progressively-infected cats in Group 3 was likely a focal FeLV infection. Two other presumptively progressively-infected cats in Group 3 may have been classified as regressive infections with repeated testing, highlighting the difficulties associated with FeLV diagnosis when sampling cats at a single time point, even with results from a panel of FeLV tests. These results serve as a reminder to Australian veterinarians that the threat of FeLV to the general pet cat population remains high, thus vigilant FeLV testing, separate housing for FeLV-infected cats, and FeLV vaccination of at-risk cats is important, particularly in group-housed cats in shelters and rescue facilities, where outbreaks of FeLV infection can occur.
Collapse
Affiliation(s)
- Mark Westman
- Sydney School of Veterinary Science, The University of Sydney, Camperdown, 2006 NSW, Australia.
| | - Jacqueline Norris
- Sydney School of Veterinary Science, The University of Sydney, Camperdown, 2006 NSW, Australia.
| | - Richard Malik
- Centre for Veterinary Education, The University of Sydney, Camperdown, 2006 NSW, Australia.
| | - Regina Hofmann-Lehmann
- Clinical Laboratory and Centre for Clinical Studies, Vetsuisse Faculty, The University of Zurich, CH-8057 Zürich, Switzerland.
| | - Andrea Harvey
- Small Animal Specialist Hospital, 1 Richardson Place, North Ryde, Sydney, 2113 NSW, Australia.
| | - Alicia McLuckie
- Sydney School of Veterinary Science, The University of Sydney, Camperdown, 2006 NSW, Australia.
| | | | | | - Alan Marcus
- Sydney School of Veterinary Science, The University of Sydney, Camperdown, 2006 NSW, Australia.
| | - Mike McDonald
- Veterinary Diagnostic Services, The University of Glasgow, Glasgow, Scotland G61 1QH, UK.
| | - Michael Ward
- Sydney School of Veterinary Science, The University of Sydney, Camden, 2570 NSW, Australia.
| | - Evelyn Hall
- Sydney School of Veterinary Science, The University of Sydney, Camden, 2570 NSW, Australia.
| | - Paul Sheehy
- Sydney School of Veterinary Science, The University of Sydney, Camden, 2570 NSW, Australia.
| | - Margaret Hosie
- MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, UK.
| |
Collapse
|
8
|
Sahay B, Yamamoto JK. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine. Viruses 2018; 10:v10050277. [PMID: 29789450 PMCID: PMC5977270 DOI: 10.3390/v10050277] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 05/08/2018] [Accepted: 05/20/2018] [Indexed: 11/16/2022] Open
Abstract
The feline immunodeficiency virus (FIV) vaccine called Fel-O-Vax® FIV is the first commercial FIV vaccine released worldwide for the use in domestic cats against global FIV subtypes (A⁻E). This vaccine consists of inactivated dual-subtype (A plus D) FIV-infected cells, whereas its prototype vaccine consists of inactivated dual-subtype whole viruses. Both vaccines in experimental trials conferred moderate-to-substantial protection against heterologous strains from homologous and heterologous subtypes. Importantly, a recent case-control field study of Fel-O-Vax-vaccinated cats with outdoor access and ≥3 years of annual vaccine boost, resulted in a vaccine efficacy of 56% in Australia where subtype-A viruses prevail. Remarkably, this protection rate is far better than the protection rate of 31.2% observed in the best HIV-1 vaccine (RV144) trial. Current review describes the findings from the commercial and prototype vaccine trials and compares their immune correlates of protection. The studies described in this review demonstrate the overarching importance of ant-FIV T-cell immunity more than anti-FIV antibody immunity in affording protection. Thus, future efforts in developing the next generation FIV vaccine and the first effective HIV-1 vaccine should consider incorporating highly conserved protective T-cell epitopes together with the conserved protective B-cell epitopes, but without inducing adverse factors that eliminate efficacy.
Collapse
Affiliation(s)
- Bikash Sahay
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, P.O. Box 110880, Gainesville, FL 32611-0880, USA.
| | - Janet K Yamamoto
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, P.O. Box 110880, Gainesville, FL 32611-0880, USA.
| |
Collapse
|
9
|
Grosenbaugh DA, Frances-Duvert V, Abedi S, Feilmeier B, Ru H, Poulet H. Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions. Biologicals 2017; 49:76-80. [PMID: 28734742 DOI: 10.1016/j.biologicals.2016.10.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 09/19/2016] [Accepted: 10/17/2016] [Indexed: 11/25/2022] Open
Abstract
The purpose of this study was to compare the efficacy of three FeLV vaccines, under identical conditions in a laboratory challenge model that closely mimics natural infection. Four groups of cats (n = 20 per group) were administered two doses of vaccine, 21 days apart, starting at 9-10 weeks of age (Purevax® FeLV, Versifel® FeLV, Nobivac® feline 2-FeLV, and a placebo). Cats were challenged 3 weeks later with a virulent, heterologous FeLV isolate. FeLV antigenemia was determined at weekly intervals from 3 to 15 weeks postchallenge. Circulating proviral DNA was determined on terminal PBMC samples. Following challenge, persistent antigenemia developed in 15 (75%) placebo-vaccinated cats, 3 (15%) cats in the Versifel FeLV vaccinated group, and 1 cat (5%) each in the Purevax FeLV and the Nobivac FeLV vaccinated groups. The prevented fractions for three vaccine groups were 93%, 93%, and 80% respectively. The adjusted p-values for all vaccine group comparisons fail to approach statistical significance. There was excellent agreement between proviral FeLV DNA in circulating PBMCs and persistent antigenemia. It is shown that when cats are managed under the same conditions during a virulent challenge, via the normal route of infection, the tested vaccines all show a comparable degree of protection.
Collapse
Affiliation(s)
| | - Valérie Frances-Duvert
- Merial, Research and Development, Lyon Gerland Laboratories, 254 rue Marcel Mérieux, 69007, Lyon, France
| | - Shabnam Abedi
- Merial, Research and Development, 1730 Olympic Dr., Athens, GA 30601, USA
| | - Bradley Feilmeier
- Merial, Research and Development, 1730 Olympic Dr., Athens, GA 30601, USA
| | - Hongyu Ru
- Merial, Research and Development, 1730 Olympic Dr., Athens, GA 30601, USA
| | - Hervé Poulet
- Merial, Research and Development, Lyon Gerland Laboratories, 254 rue Marcel Mérieux, 69007, Lyon, France
| |
Collapse
|
10
|
Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M. Reply to "Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines". Clin Vaccine Immunol 2015; 22:1296-7. [PMID: 26604265 DOI: 10.1128/CVI.00504-15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
11
|
Poulet H, Thibault JC, Masias A. Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines. Clin Vaccine Immunol 2015; 22:1294-5. [PMID: 26604264 DOI: 10.1128/CVI.00497-15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
12
|
Möstl K, Addie DD, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, Marsilio F, Pennisi MG, Radford AD, Thiry E, Truyen U, Horzinek MC. Something old, something new: Update of the 2009 and 2013 ABCD guidelines on prevention and management of feline infectious diseases. J Feline Med Surg 2015; 17:570-82. [PMID: 26101308 DOI: 10.1177/1098612x15588448] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OVERVIEW The ABCD has published 34 guidelines in two Special Issues of the Journal of Feline Medicine and Surgery (JFMS): the first in July 2009 (Volume 11, Issue 7, pages 527-620) and the second in July 2013 (Volume 15, Issue 7, pages 528-652). The present article contains updates and new information on 18 of these (17 disease guidelines and one special article 'Prevention of infectious diseases in cat shelters'). For detailed information, readers are referred to the guidelines published in the above-mentioned JFMS Special Issues.
Collapse
|
13
|
Abstract
The intricate sequence and antigenic variability of avian leukosis virus subgroup J (ALV-J) have led to unprecedented difficulties in the development of vaccines. Much experimental evidence demonstrates that ALV-J mutants have caused immune evasion and pose a challenge for traditional efforts to develop effective vaccines. To investigate the potential of a multi-epitope vaccination strategy to prevent chickens against ALV-J infections, a recombinant chimeric multi-epitope protein X (rCMEPX) containing both immunodominant B and T epitope concentrated domains selected from the major structural protein of ALV-J using bioinformatics approach was expressed in Escherichia coli Rosetta (DE3). Its immunogenicity and protective efficacy was studied in chickens. The results showed that rCMEPX could elicit neutralizing antibodies and cellular responses, and antibodies induced by rCMEPX could specifically recognize host cell naturally expressed ALV-J proteins, which indicated that the rCMEPX is a good immunogen. Challenge experiments showed 80% chickens that received rCMEPX were well protected against ALV-J challenge. This is the first report of a chimeric multi-epitope protein as a potential immunogen against ALV-J.
Collapse
Affiliation(s)
- Qingqing Xu
- Department of Preventive Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China; Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China
| | - Xingjiang Ma
- Department of Preventive Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China; Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China
| | - Fangkun Wang
- Department of Preventive Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China; Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China
| | - Hongmei Li
- Department of Preventive Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China; Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China
| | - Xiaomin Zhao
- Department of Preventive Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China; Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City, Shandong Province 271018, China.
| |
Collapse
|
14
|
Stuke K, King V, Southwick K, Stoeva M, Thomas A, Winkler M. In response to Letter to the Editor (Regina Hofmann-Lehmann, Laura S. Levy and Brian Willett)—Comparing the efficacy of FeLV vaccines. Vaccine 2015; 33:2739-2740. [DOI: 10.1016/j.vaccine.2015.01.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 01/16/2015] [Accepted: 01/26/2015] [Indexed: 11/18/2022]
|
15
|
Kimsa-Dudek M, Strzalka-Mrozik B, Kimsa MW, Blecharz I, Gola J, Skowronek B, Janiszewski A, Lipinski D, Zeyland J, Szalata M, Slomski R, Mazurek U. Screening pigs for xenotransplantation: expression of porcine endogenous retroviruses in transgenic pig skin. Transgenic Res 2015; 24:529-36. [PMID: 25812516 DOI: 10.1007/s11248-015-9871-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 03/23/2015] [Indexed: 01/30/2023]
Abstract
Pigs seem to be the answer to worldwide organ donor shortage. Porcine skin may also be applied as a dressing for severe burns. Genetic modifications of donor animals enable reduction of immune response, which prolongs xenograft survival as temporary biological dressing and allows achieving resistance against xenograft rejection. The risk posed by porcine endogenous retroviruses (PERVs) cannot be eliminated by breeding animals under specific-pathogen-free conditions and so all recipients of porcine graft will be exposed to PERVs. Therefore our study has been focused on the assessment of PERV DNA and mRNA level in skin samples of transgenic pigs generated for xenotransplantation. Porcine skin fragments were obtained from 3- to 6-month-old non-transgenic and transgenic Polish Landrace pigs. Transgenic pigs were produced by pronuclear DNA microinjection and were developed to express the human α-galactosidase and the human α-1,2-fucosyltransferase gene. The copy numbers of PERV DNA and RNA were evaluated using real-time Q-PCR and QRT-PCR. Comparative analysis of all PERV subtypes revealed that PERV-A is the main subtype of PERVs in analyzed skin samples. There was no significantly different copy number of PERV-A, PERV-B and PERV-C between non-transgenic pigs, pigs with the human α-galactosidase and pigs expressing the human α-1,2-fucosyltransferase gene, except of PERV-C DNA. It brings the conclusion, that transgenesis process exerts no influence on PERVs transinfection. That is another step forward in the development of pig skin xenografts as burn wounds dressing.
Collapse
Affiliation(s)
- Magdalena Kimsa-Dudek
- Department of Food and Nutrition, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Jednosci 8, 41-200, Sosnowiec, Poland,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression. Clin Vaccine Immunol 2015; 22:798-805. [PMID: 25972402 DOI: 10.1128/CVI.00034-15] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 04/22/2015] [Indexed: 11/24/2022]
Abstract
Four vaccines for feline leukemia virus (FeLV) are available in the United States. This study's purpose was to compare the efficacy of Nobivac feline 2-FeLV (an inactivated, adjuvanted whole-virus vaccine) and PureVax recombinant FeLV (a live, canarypox virus-vectored vaccine) following FeLV challenge. Cats were vaccinated at 9 and 12 weeks with Nobivac feline 2-FeLV (group A, n = 11) or PureVax recombinant FeLV (group B, n = 10). Group C (n = 11) comprised unvaccinated controls. At 3 months postvaccination, cats were immunosuppressed and challenged with FeLV-A/61E. The outcomes measured were persistent antigenemia at 12 weeks postchallenge (PC) and proviral DNA and viral RNA at 3 to 9 weeks PC. Persistent antigenemia was observed in 0 of 11 cats in group A, 5 of 10 cats in group B, and 10 of 11 cats in group C. Group A was significantly protected compared to those in groups B (P < 0.013) and C (P < 0.0001). No difference was found between groups B and C (P > 0.063). The preventable fraction was 100% for group A and 45% for group B. At 9 weeks PC, proviral DNA and viral RNA were detected 1 of 11 cats in group A, 6 of 10 cats in group B, and 9 of 11 cats in group C. Nucleic acid loads were significantly lower in group A than in group C (P < 0.01). Group A had significantly lower proviral DNA loads than group B at weeks 6 to 9 (P < 0.02). The viral RNA loads were significantly lower in group A than in group B at weeks 7 to 9 (P < 0.01). The results demonstrate that Nobivac feline 2-FeLV-vaccinated cats were fully protected against persistent antigenemia and had significantly smaller amounts of proviral DNA and plasma viral RNA loads than PureVax recombinant FeLV-vaccinated cats and unvaccinated controls.
Collapse
|
17
|
Helfer-Hungerbuehler AK, Spiri AM, Riond B, Grest P, Boretti FS, Hofmann-Lehmann R. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus. Vaccine 2015; 33:1578-85. [PMID: 25698488 DOI: 10.1016/j.vaccine.2015.02.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 02/04/2015] [Indexed: 11/22/2022]
Abstract
Therapeutic vaccinations have a potential application in infections where no curative treatment is available. In contrast to HIV, efficacious vaccines for a cat retrovirus, feline leukemia virus (FeLV), are commercially available. However, the infection is still prevalent, and no effective treatment of the infection is known. By vaccinating persistently FeLV-infected cats and presenting FeLV antigens to the immune system of the host, e.g., in the form of recombinant and/or adjuvanted antigens, we intended to shift the balance toward an advantage of the host so that persistent infection could be overcome by the infected cat. Two commercially available FeLV vaccines efficacious in protecting naïve cats from FeLV infection were tested in six experimentally and persistently FeLV-infected cats: first, a canarypox-vectored vaccine, and second, an adjuvanted, recombinant envelope vaccine was repeatedly administered with the aim to stimulate the immune system. No beneficial effects on p27 antigen and plasma viral RNA loads, anti-FeLV antibodies, or life expectancy of the cats were detected. The cats were unable to overcome or decrease viremia. Some cats developed antibodies to FeLV antigens although not protective. Thus, we cannot recommend vaccinating persistently FeLV-infected cats as a means of improving their FeLV status, quality of life or life expectancy. We suggest testing of all cats for FeLV infection prior to FeLV vaccination.
Collapse
|
18
|
Helfer-Hungerbuehler AK, Widmer S, Kessler Y, Riond B, Boretti FS, Grest P, Lutz H, Hofmann-Lehmann R. Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes. Virus Res 2015; 197:137-50. [DOI: 10.1016/j.virusres.2014.12.025] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 12/18/2014] [Accepted: 12/19/2014] [Indexed: 10/24/2022]
|
19
|
Beatty J. Viral causes of feline lymphoma: Retroviruses and beyond. Vet J 2014; 201:174-80. [DOI: 10.1016/j.tvjl.2014.05.026] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 05/11/2014] [Accepted: 05/17/2014] [Indexed: 11/30/2022]
|
20
|
Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol 2014; 21:1023-36. [PMID: 24920599 DOI: 10.1128/CVI.00230-14] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Animal and human data from various viral infections and vaccine studies suggest that nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important role in protection against viral infection in vivo. This was illustrated by the recent human immunodeficiency virus (HIV) RV144 vaccine efficacy trial, which demonstrated that HIV-specific IgG-mediated nNAb directed against the V2 loop of HIV type 1 envelope (Env) were inversely correlated with risk for HIV acquisition, while Env-specific plasma IgA-mediated antibodies were directly correlated with risk. However, tier 1 NAb in the subset of responders with a low level of plasma Env-specific IgA correlated with decreased risk. Nonhuman primate simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) challenge studies suggest that Env-mediated antibodies are essential and sufficient for protection. A comparison of immune responses generated in human efficacy trials reveals subtle differences in the fine specificities of the antibody responses, in particular in HIV-specific IgG subclasses. The underlying mechanisms that may have contributed to protection against HIV acquisition in humans, although not fully understood, are possibly mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) and/or other nonneutralizing humoral effector functions, such as antibody-mediated phagocytosis. The presence of such functional nNAb in mucosal tissues and cervico-vaginal and rectal secretions challenges the paradigm that NAb are the predominant immune response conferring protection, although this does not negate the desirability of evoking neutralizing antibodies through vaccination. Instead, NAb and nNAb should be looked upon as complementary or synergistic humoral effector functions. Several HIV vaccine clinical trials to study these antibody responses in various prime-boost modalities in the systemic and mucosal compartments are ongoing. The induction of high-frequency HIV-specific functional nNAb at high titers may represent an attractive hypothesis-testing strategy in future HIV vaccine efficacy trials.
Collapse
|
21
|
|
22
|
Schlecht-Louf G, Mangeney M, El-Garch H, Lacombe V, Poulet H, Heidmann T. A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine. J Virol 2014; 88:992-1001. [PMID: 24198407 DOI: 10.1128/JVI.02234-13] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
We previously delineated a highly conserved immunosuppressive (IS) domain within murine and primate retroviral envelope proteins that is critical for virus propagation in vivo. The envelope-mediated immunosuppression was assessed by the ability of the proteins, when expressed by allogeneic tumor cells normally rejected by engrafted mice, to allow these cells to escape, at least transiently, immune rejection. Using this approach, we identified key residues whose mutation (i) specifically abolishes immunosuppressive activity without affecting the "mechanical" function of the envelope protein and (ii) significantly enhances humoral and cellular immune responses elicited against the virus. The objective of this work was to study the immunosuppressive activity of the envelope protein (p15E) of feline leukemia virus (FeLV) and evaluate the effect of its abolition on the efficacy of a vaccine against FeLV. Here we demonstrate that the FeLV envelope protein is immunosuppressive in vivo and that this immunosuppressive activity can be "switched off" by targeted mutation of a specific amino acid. As a result of the introduction of the mutated envelope sequence into a previously well characterized canarypox virus-vectored vaccine (ALVAC-FeLV), the frequency of vaccine-induced FeLV-specific gamma interferon (IFN-γ)-producing cells was increased, whereas conversely, the frequency of vaccine-induced FeLV-specific interleukin-10 (IL-10)-producing cells was reduced. This shift in the IFN-γ/IL-10 response was associated with a higher efficacy of ALVAC-FeLV against FeLV infection. This study demonstrates that FeLV p15E is immunosuppressive in vivo, that the immunosuppressive domain of p15E can modulate the FeLV-specific immune response, and that the efficacy of FeLV vaccines can be enhanced by inhibiting the immunosuppressive activity of the IS domain through an appropriate mutation.
Collapse
|
23
|
Wilson S, Greenslade J, Saunders G, Holcroft C, Bruce L, Scobey A, Childers T, Sture G, Thompson J. Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection. BMC Vet Res 2012; 8:125. [PMID: 22839692 PMCID: PMC3433334 DOI: 10.1186/1746-6148-8-125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Accepted: 07/12/2012] [Indexed: 11/19/2022] Open
Abstract
Background Feline leukaemia virus (FeLV) is a pathogen causing fatal illness in cats worldwide, and as such there is a high demand for products to protect against disease. The duration of immunity provided by an inactivated FeLV vaccine, Versifel FeLV, when administered to cats of the target age was determined. Kittens received two vaccinations when aged 7 to 9 weeks old, and were subsequently challenged up to 36 months later with the FeLV-A Glasgow isolate. Results In all studies, all of the younger aged control kittens showed persistent FeLV p27 antigenaemia confirming that the challenge virus was severe and efficacious. In contrast, the control cats did not show the required level of persistent antigenaemia, with a maximum of 45% cats affected in the middle duration study and only 10% in the longer study. However, apart from one animal in the short duration study, all of the cats vaccinated with Versifel FeLV were negative for persistent antigenaemia and can be considered treatment successes. Conclusion In conclusion, we have shown that although age-related resistance to infection with a virulent FeLV challenge is evident from as early as 10 months of age, vaccination with Versifel FeLV may aid in the protection of cats from FeLV related disease up to three years after primary vaccination as kittens.
Collapse
Affiliation(s)
- Stephen Wilson
- Veterinary Medicine Research and Development, Pfizer Animal Health, Pfizer European Service Centre, Zaventem, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Xenotransplantation may be a solution to overcome the shortage of organs for the treatment of patients with organ failure, but it may be associated with the transmission of porcine microorganisms and the development of xenozoonoses. Whereas most microorganisms may be eliminated by pathogen-free breeding of the donor animals, porcine endogenous retroviruses (PERVs) cannot be eliminated, since these are integrated into the genomes of all pigs. Human-tropic PERV-A and -B are present in all pigs and are able to infect human cells. Infection of ecotropic PERV-C is limited to pig cells. PERVs may adapt to host cells by varying the number of LTR-binding transcription factor binding sites. Like all retroviruses, they may induce tumors and/or immunodeficiencies. To date, all experimental, preclinical, and clinical xenotransplantations using pig cells, tissues, and organs have not shown transmission of PERV. Highly sensitive and specific methods have been developed to analyze the PERV status of donor pigs and to monitor recipients for PERV infection. Strategies have been developed to prevent PERV transmission, including selection of PERV-C-negative, low-producer pigs, generation of an effective vaccine, selection of effective antiretrovirals, and generation of animals transgenic for a PERV-specific short hairpin RNA inhibiting PERV expression by RNA interference.
Collapse
|
25
|
|
26
|
|
27
|
Beatty JA, Tasker S, Jarrett O, Lam A, Gibson S, Noe-Nordberg A, Phillips A, Fawcett A, Barrs VR. Markers of Feline Leukaemia Virus Infection or Exposure in Cats from a Region of Low Seroprevalence. J Feline Med Surg 2011; 13:927-33. [PMID: 21880527 DOI: 10.1016/j.jfms.2011.07.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2011] [Revised: 07/11/2011] [Accepted: 07/16/2011] [Indexed: 11/18/2022]
Abstract
Molecular techniques have demonstrated that cats may harbour feline leukaemia virus (FeLV) provirus in the absence of antigenaemia. Using quantitative real-time polymerase chain reaction (qPCR), p27 enzyme-linked immunosorbent assay (ELISA), anti-feline oncornavirus-associated cell-membrane-antigen (FOCMA) antibody testing and virus isolation (VI) we investigated three groups of cats. Among cats with cytopenias or lymphoma, 2/75 were transiently positive for provirus and anti-FOCMA antibodies were the only evidence of exposure in another. In 169 young, healthy cats, all tests were negative. In contrast, 3/4 cats from a closed household where FeLV was confirmed by isolation, had evidence of infection. Our results support a role for factors other than FeLV in the pathogenesis of cytopenias and lymphoma. There was no evidence of exposure in young cats. In regions of low prevalence, where the positive predictive value of antigen testing is low, qPCR may assist with diagnosis.
Collapse
Affiliation(s)
- Julia A Beatty
- Valentine Charlton Cat Centre, Faculty of Veterinary Science, The University of Sydney, NSW 2006, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Little S, Bienzle D, Carioto L, Chisholm H, O'Brien E, Scherk M. Feline leukemia virus and feline immunodeficiency virus in Canada: recommendations for testing and management. Can Vet J 2011; 52:849-55. [PMID: 22294790 PMCID: PMC3135027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are common and important infectious disease agents of cats in Canada. Seroprevalence data for FeLV and FIV in various populations of Canadian cats are reviewed and recommendations for testing and management of infections by these viruses in cats in Canada are presented. Retrovirus testing in Canada is infrequent in comparison with the United States, and efforts should be focused on reducing physical and other barriers to testing, and on education of veterinarians, veterinary team members, and cat owners regarding the importance of testing. New test methodologies for FeLV and FIV are emerging, and should be independently evaluated in order to provide practitioners with information on test reliability. Finally, more information is needed on FIV subtypes in Canada to improve diagnostics and vaccines, and to provide information on disease outcomes.
Collapse
|
29
|
Coelho F, Maia M, Luppi M, Costa E, Luiz A, Ribeiro N, Bomfim M, Fonseca F, Resende M. Ocorrência do vírus da leucemia felina em Felis cattus em Belo Horizonte. ARQ BRAS MED VET ZOO 2011. [DOI: 10.1590/s0102-09352011000300037] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
30
|
Kaulitz D, Mihica D, Plesker R, Geissler A, Tönjes RR, Denner J. Absence of infection in pigs inoculated with high-titre recombinant PERV-A/C. Arch Virol 2011; 156:707-10. [PMID: 21197554 DOI: 10.1007/s00705-010-0896-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Accepted: 12/15/2010] [Indexed: 11/27/2022]
Abstract
Porcine endogenous retroviruses (PERVs) represent a risk for xenotransplantation using pig cells or organs since they are integrated in the genome of all pigs and infect human cells in vitro. Recombinants between PERV-A and PERV-C have been described in pigs in vivo and found de novo integrated in the genome of somatic cells, but not in the germ line. To study whether PERV-A/C can infect and have a pathogenic effect in normal pigs, German landrace pigs were inoculated with high-titre PERV-A/C. No provirus integration was found in blood cells or in various tissues, and no antibody production was observed, indicating the absence of infection.
Collapse
|
31
|
Affiliation(s)
- KyeongEun Lee
- Model Development Section, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, Maryland 21702, USA.
| | | |
Collapse
|